Tag Archives: EPZM

Cowen & Co. Thinks Epizyme’s Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $8.30, close to its 52-week low of $7.61. According to TipRanks.com, Nadeau is a 5-star analyst with an average

Oppenheimer Thinks Epizyme’s Stock is Going to Recover

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $27. The company’s shares opened today at $8.30, close to its 52-week low of $7.74. Cann wrote:

Epizyme (EPZM) Initiated with a Hold at Leerink Partners

Leerink Partners analyst Geoff Porges initiated coverage with a Hold rating on Epizyme (NASDAQ: EPZM) today and set a price target of $11. The company’s shares closed yesterday at $10.25, close to its 52-week low of $8.61. According to TipRanks.com,

Cowen & Co. Sticks to Its Buy Rating for Epizyme (EPZM)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $11.45. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.2% and a 56.4% success

Roth Capital Thinks Epizyme’s Stock is Going to Recover

In a report released today, Jotin Marango from Roth Capital reiterated a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $26. The company’s shares closed on Friday at $10.25, close to its 52-week low of $8.61. Marango

Epizyme (EPZM) Received its Third Buy in a Row

After Oppenheimer and Cowen & Co. gave Epizyme (NASDAQ: EPZM) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein reiterated a Buy rating on Epizyme today and set a price target